Quarterly Results

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

โ€ข Phase I/2a clinical trials initiated: VMT-๐›ผ-NET for neuroendocrine tumors, and VMT01 for melanoma…

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

* Additional CDMO capabilities added to increase availability of clinical trial product in the US
* Phase I/IIa studies are initiating in the first half of 2023 for VMT- ๐›ผ-NET for neuroendocrine tumors and VMT-01 for melanoma

Scroll to top